» Toleranzia completes pilot batch of TOL2
» Wales used PolarCool's concussion treatment at the World Cup
» Arcede Pharma prepares for clinical studies
» Broad rise in Scandion after incoming CEO and insider buying
» Spago Nanomedical starts phase IIa study in endometriosis
Read BioStock's newsletter for v.48 here.
On November 29-30, BioStock Life Science Summit held at Medicon Village in Lund. Keep an eye out for our website for video footage from the event!
Morning news
Iconovos inhaler platform ICOone receives new patent approval in the USA. Read more.
Idefirix (imlifidase) granted national subsidy in Italy for highly sensitized kidney transplant patients, announces Hansa Biopharma. Read more.
Sedana Medicals Sedaconda (isoflurane) has received market approval in Poland. Read more.
Rights issue in Sprint Bioscience is registered and trading in BTU ceases. Read more.
Senzime receives the first contract regarding TetraSens Pediatric in the United States. Read more.
AlphaHelix subsidiary Cybergene establishes agreement with new distributor. Read more.
An agreement has been signed between Ziccum and ZHAW about a 3D modeling project. Read more.
In study at Lumitos UCNP technology has been published in Cancer Immunology Research. Read more.
Targovax has published the financial calendar for 22/23. Read more.
SUFFER will present at Science4Peace in connection with the Nobel celebration. Read more.
Peptonic Medicals subsidiary Bezel has received an order from the UN. Read more.
BergenBio will present at the DNB Nordic Healthcare Conference. Read more.
Amniotic The liquidity guarantee agreement is terminated, the company announces. Read more.
The shares in Alvotech start trading on Nasdaq Iceland starting today. Read more.
Probis board appoints Anita Johansen to interim CEO. Read more.
New research at University of Gothenburg could pave the way for a solution to today's overtreatment of prostate cancer. Read more.
A new method for mapping cancer cells provides insights for treating incurable brain cancer in children, announces Stockholm University. Read more.
Notice of general meeting
Peptonic Medical
Communiqués:
Attana
News since Wednesday lunch
Elicera Therapeutics reports clear signals of clinical activity from patients with neuroendocrine tumors in the study with ELC-100 vid Oncolytic Virotherapy Summit 2022. Read more.
Vicore Pharma has carried out a directed new share issue of 10 million shares and will receive gross proceeds of SEK 200 million. Read more.
Oncopeptides has updated the marketing authorisation for Pepaxto in the United States. Read more.
Significantly prolonged overall survival has been demonstrated in the phase III study DESTINY-Breast03 w/ Enhertu av AstraZeneca. Read more.
ArcticZymes Technologies licenses new DNA assembly technology. Read more.
WntResearch participates in the Shareholders' Association's share meeting on December 12. Read more.
The compensation issue in connection with the rights issue in Cessatech has been registered. Read more.
Cline Scientific announces the outcome of the rights issue. Read more (amendment).
SpectraCure has signed a letter of intent with Cheplapharm respect Q-PRO. Read more.
Home check has received a follow-up order from German Heart Center Berlin. Read more.
Marking comments on debt and financing situation and the delayed introduction of quarterly reporting. Read more.
This morning's price development
Winner: Xbrane Biopharma 10,1%, Aino Health 9,6%, Bioservo Technologies 8,3%, Sprint Bioscience 8,2%, Cancel 6,9%
Förlorare: VO2 Cap Holding -13,2%, aXichem -9,0%, AlzeCure Pharma -8,9%, Bonzun -8,8%, Vicore Pharma -7,7%
Index: OMXS30 2094 0,28%, Healthcare -0,21%
More from BioStock
» Cereno's CIPO comments on the company's strong patent portfolio
» Iconovo invests in pharmaceutical sales in the Nordics
» Uppsala's life science sector continues to grow
» Alzinova's CSO on the presentation of ALZ-201 at CTAD
» Curasight optimistic about phase II results in brain cancer